Trial Profile
Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs IMC TR1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company; ImClone Systems
- 28 Oct 2014 Planned End Date changed from 1 Mar 2015 to 1 Oct 2014, according to ClinicalTrials.gov
- 28 Oct 2014 Planned primary completion date changed from 1 Mar 2015 to 1 Oct 2014, according to ClinicalTrials.gov
- 09 Sep 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.